Q1 EPS Estimates for Henry Schein Lowered by Zacks Research

Henry Schein, Inc. (NASDAQ:HSIC) – Stock analysts at Zacks Research decreased their Q1 2025 earnings per share estimates for shares of Henry Schein in a note issued to investors on Tuesday, March 18th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $1.11 for the quarter, down from their prior estimate of $1.17. The consensus estimate for Henry Schein’s current full-year earnings is $4.74 per share. Zacks Research also issued estimates for Henry Schein’s Q2 2025 earnings at $1.21 EPS, Q3 2025 earnings at $1.26 EPS, Q4 2025 earnings at $1.26 EPS, FY2025 earnings at $4.84 EPS, Q1 2026 earnings at $1.32 EPS, Q2 2026 earnings at $1.36 EPS, Q3 2026 earnings at $1.25 EPS, Q4 2026 earnings at $1.39 EPS, FY2026 earnings at $5.31 EPS and FY2027 earnings at $5.74 EPS.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings data on Tuesday, February 25th. The company reported $1.19 earnings per share for the quarter, missing analysts’ consensus estimates of $1.23 by ($0.04). Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The business had revenue of $3.19 billion during the quarter, compared to the consensus estimate of $3.25 billion. During the same quarter in the previous year, the firm posted $0.66 earnings per share. The company’s revenue was up 5.8% compared to the same quarter last year.

HSIC has been the topic of a number of other reports. Wells Fargo & Company started coverage on Henry Schein in a research note on Friday, February 14th. They issued an “equal weight” rating and a $80.00 price target on the stock. Bank of America raised shares of Henry Schein from an “underperform” rating to a “buy” rating and lifted their target price for the stock from $69.00 to $84.00 in a research note on Monday, January 6th. Mizuho started coverage on shares of Henry Schein in a research report on Wednesday, December 4th. They set a “neutral” rating and a $75.00 price target for the company. UBS Group decreased their price objective on shares of Henry Schein from $83.00 to $80.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 26th. Finally, Barrington Research reiterated an “outperform” rating and set a $90.00 target price on shares of Henry Schein in a report on Wednesday, February 26th. Six research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Henry Schein currently has an average rating of “Moderate Buy” and a consensus target price of $81.10.

Henry Schein Stock Down 0.6 %

Shares of NASDAQ:HSIC opened at $70.45 on Thursday. The stock has a market capitalization of $8.75 billion, a P/E ratio of 28.99, a price-to-earnings-growth ratio of 2.13 and a beta of 0.90. The stock’s 50-day moving average price is $74.83 and its 200-day moving average price is $72.61. The company has a current ratio of 1.42, a quick ratio of 0.82 and a debt-to-equity ratio of 0.46. Henry Schein has a 12-month low of $63.67 and a 12-month high of $82.49.

Institutional Investors Weigh In On Henry Schein

Hedge funds have recently added to or reduced their stakes in the stock. Versant Capital Management Inc boosted its stake in Henry Schein by 274.6% in the 4th quarter. Versant Capital Management Inc now owns 457 shares of the company’s stock worth $32,000 after purchasing an additional 335 shares in the last quarter. Investment Management Corp VA ADV bought a new position in shares of Henry Schein in the fourth quarter worth approximately $32,000. Venturi Wealth Management LLC grew its holdings in shares of Henry Schein by 3,347.1% during the fourth quarter. Venturi Wealth Management LLC now owns 586 shares of the company’s stock valued at $41,000 after buying an additional 569 shares during the last quarter. Quent Capital LLC increased its position in shares of Henry Schein by 91.2% during the fourth quarter. Quent Capital LLC now owns 677 shares of the company’s stock valued at $47,000 after acquiring an additional 323 shares in the last quarter. Finally, Smartleaf Asset Management LLC raised its holdings in Henry Schein by 23.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 759 shares of the company’s stock worth $52,000 after acquiring an additional 143 shares during the last quarter. 96.62% of the stock is owned by institutional investors.

Insider Activity

In related news, Director Philip A. Laskawy sold 2,604 shares of the business’s stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $71.04, for a total transaction of $184,988.16. Following the sale, the director now owns 24,805 shares of the company’s stock, valued at $1,762,147.20. The trade was a 9.50 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Bradford C. Connett sold 4,036 shares of the company’s stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $71.15, for a total transaction of $287,161.40. Following the completion of the sale, the chief executive officer now owns 62,688 shares in the company, valued at approximately $4,460,251.20. This trade represents a 6.05 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.14% of the company’s stock.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.